



HAL
open science

Effect of Prophylaxis for Early Adrenal Insufficiency Using Low-Dose Hydrocortisone in Very Preterm Infants: An Individual Patient Data Meta-Analysis

Michele Shaffer, Olivier Baud, Thierry Lacaze-Masmonteil, Outi Peltoniemi, Francesco Bonsante, Kristi Watterberg

► **To cite this version:**

Michele Shaffer, Olivier Baud, Thierry Lacaze-Masmonteil, Outi Peltoniemi, Francesco Bonsante, et al.. Effect of Prophylaxis for Early Adrenal Insufficiency Using Low-Dose Hydrocortisone in Very Preterm Infants: An Individual Patient Data Meta-Analysis. *Journal of Pediatrics*, Elsevier, 2018, 10.1016/j.jpeds.2018.10.004 . hal-02015108

HAL Id: hal-02015108

<https://hal.univ-reunion.fr/hal-02015108>

Submitted on 22 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial | 4.0 International License

to improve survival without BPD.¹¹⁻¹⁵ These trials extended hydrocortisone therapy beyond the first postnatal week and used a dose of 1-2 mg/kg/day, which has been shown to moderately but significantly increase serum cortisol concentrations in extremely preterm neonates compared with placebo.¹²

Although 2-year follow-up data have been consistently reassuring,^{7,16-19} the effect of early hydrocortisone treatment on survival without BPD and potential side effects remain unclear. Therefore, we undertook an individual patient data meta-analysis of clinical trials to examine the effect of prophylaxis of early adrenal insufficiency on these outcomes.

Methods

The PRISMA-IPD checklist of items requested to report a meta-analysis of individual patient data is available at www.jpeds.com (**Supplement**). In addition, some data items are available in the statistical analysis plan (**Appendix**; available at www.jpeds.com). Two meta-analyses identified published RCTs of early hydrocortisone therapy conducted before 2017.^{7,20} We also searched MEDLINE for the terms “hydrocortisone,” “cortisone,” “preterm infant,” “randomized,” and “human.” The last search was done in July 2018. We did not identify any RCTs of early low-dose hydrocortisone therapy to prevent BPD other than those included in these 2 reports.

Individual Patient Data Acquisition, Data Processing, and Quality Assessment

The principal investigators of the 5 eligible trials agreed to share deidentified data to perform an individual patient data meta-analysis. Individual patient data from 1 pilot trial (n = 40) were no longer available¹¹; this individual patient data meta-analysis includes all data from the remaining 4 studies (n = 982). Because an individual patient data meta-analysis can improve the ability to address confounders or covariates of interest, we were able to account for individual patient-level factors that affected outcomes, which would not have been possible with an aggregate meta-analysis based on published data without the risk of drawing potentially incorrect conclusions owing to ecological fallacy with the application of meta-regression. In addition, meta-regression often has low power to detect relationships.²¹⁻²³ Individual patient data also allowed for inclusion of data not previously reported and standardization of outcomes and exposures across studies. In addition, the cooperation of all authors of the original publications allowed for detailed data checking.

We created a common data dictionary and asked corresponding authors to identify which data elements were available, or to suggest alternative measures if data were not available. After receiving all authors' available data, we created a final data capture template to request the individual patient datasets from all authors to reduce the amount of postprocessing needed to harmonize the datasets. Any questions regarding the individual patient datasets were discussed with the authors and corrected.

The statistician created any necessary derived variables and checked the summary statistics against available published data.

All data summaries by study and treatment group were shared with the corresponding authors to check for discrepancies, and any identified errors were corrected.

Outcomes and Subgroups of Interest

The primary outcome of interest was the binary variable survival without BPD at 36 weeks postmenstrual age (PMA), and the primary predictor was receipt of early low-dose hydrocortisone treatment. Adjustment variables to be included in all models were birth weight, sex, gestational age, and antenatal steroid use. Predefined subgroups of interest included sex, histologic chorioamnionitis, gestational age strata (<26 or ≥26 weeks), and indomethacin treatment.

Secondary outcomes included days of ventilation, continuous positive airway pressure, and oxygen; supplemental oxygen at discharge; and medical or surgical treatment for patent ductus arteriosus (PDA). Prespecified potential adverse outcomes included pneumothorax, spontaneous gastrointestinal perforation, necrotizing enterocolitis, severe intraventricular hemorrhage, cystic periventricular leukomalacia, severe retinopathy of prematurity, late-onset sepsis (bacterial or fungal), and the effects of hydrocortisone on weight or head circumference at 36 weeks PMA and on the 2-year neurodevelopmental outcomes.

Statistical Analyses

An a priori statistical analysis plan (**Appendix**) was created to describe and prioritize the outcomes and analyses of interest, including subgroup and sensitivity analyses, before the analysis was begun. No multiple comparisons adjustments were used for subgroup analyses. We used a 1-step approach to individual patient data meta-analysis using generalizations of logistic regression models for binary outcomes and linear regression models for quantitative outcomes based on generalized linear mixed models with Kenward-Roger approximation of degrees of freedom.^{24,25} Logistic regression models were summarized using ORs and associated 95% CIs. Linear regression models were summarized using mean differences and associated CIs. We attempted to account for clustering of patients within different studies by specifying a random intercept term, assuming that the baseline is drawn at random from a normal distribution. We first considered treatment a random effect, but then simplified the models to fixed treatment effects, which yielded similar findings in terms of magnitude, direction, and significance. Statistical heterogeneity was summarized as I^2 value and associated P value. I^2 values were computed using the meta package in R (R Foundation for Statistical Computing, Vienna, Austria). We also conducted a traditional aggregate random-effects meta-analysis based on available published data for comparison of long-term developmental outcomes.¹⁶⁻¹⁸

Statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, North Carolina) for the individual patient data analysis and using Stata 12.0 (StataCorp, College Station, Texas) for the aggregate meta-analysis. Findings were considered significant at $P < .05$.

Results

Among 11 RCTs testing hydrocortisone early after birth in neonates (Table I; available at www.jpeds.com), 5 were specifically designed to test the efficacy of prophylaxis of early adrenal insufficiency to improve survival without BPD.¹¹⁻¹⁵ The other 6 trials were excluded because of significant differences in study design, such as larger study group and use of hydrocortisone at higher doses²⁶ or for a different purpose, including refractory hemodynamic failure,²⁷⁻³⁰ or in combination with another treatment.^{26,31} The PRISMA-IPD flow diagram is depicted in the Figure (available at www.jpeds.com).

Although this individual patient data meta-analysis was not prospectively planned, the studies were quite similar in hypothesis, design, and primary outcome. As shown in Table II, patient eligibility varied slightly across the studies, as did the dose and duration of hydrocortisone therapy; however, these differences were minor and the populations were generally comparable. Table III presents summary statistics by study and treatment group for all patient characteristics and primary and secondary outcomes of interest.

Primary Outcome

Table IV presents the results of the individual patient data meta-analysis for the primary outcome and its components. Table V (available at www.jpeds.com) provides heterogeneity estimates of individual patient data meta-analysis of all outcomes unadjusted. Heterogeneity was low in most of the outcomes, with the exception of a few respiratory support items for which not all trials had data available.

Treatment with early low-dose hydrocortisone was associated with greater odds of survival without BPD at 36 weeks PMA (unadjusted OR, 1.37; 95% CI, 1.07-1.76). Findings were similar after adjustment for sex, gestational age, and antenatal

steroid use (aOR, 1.45; 95% CI, 1.11-1.90; $I^2 = 0\%$). For the components of the primary outcome, receipt of hydrocortisone was associated with significantly lower odds of BPD (aOR, 0.73; 95% CI, 0.54-0.98; $I^2 = 0\%$), but not with a significant decrease in death before 36 weeks PMA (aOR, 0.76; 95% CI, 0.54-1.07; $I^2 = 0\%$). However, hydrocortisone treatment was associated with a significant decrease in death before discharge (aOR, 0.70; 95% CI, 0.51-0.97; $I^2 = 0\%$).

Secondary Outcomes

Table IV also presents the results of the individual patient data meta-analysis for all secondary outcomes. Days of ventilation, continuous positive airway pressure, and oxygen were not significantly different between the hydrocortisone and placebo groups, and BPD severity was similar in the 2 groups. There was no significant difference in exposure to oxygen at discharge. There were significantly lower odds of any medical treatment for PDA (aOR, 0.72; 95% CI, 0.56-0.93; $I^2 = 0\%$), including both indomethacin and ibuprofen; however, there was no difference in the odds of ligation.

Exposure to hydrocortisone was associated with a significant increase in spontaneous gastrointestinal perforation (aOR, 2.50; 95% CI, 1.33-4.69; $I^2 = 31.9\%$). However, in the absence of indomethacin cotreatment, hydrocortisone was not associated with a significant increase in gastrointestinal perforation (Table VI). Exposure to hydrocortisone also was associated with significantly increased odds of late sepsis, both bacterial and fungal (aOR, 1.34; 95% CI, 1.02-1.75; $I^2 = 0\%$). This observed difference was not associated with increased mortality or other in-hospital adverse outcomes, or with any detectable adverse effect on 2-year neurodevelopmental outcomes in the hydrocortisone-treated group. There were no significant differences between the hydrocortisone and placebo groups for any of the remaining adverse outcomes (Table IV) of

Table II. Characteristics of 4 included studies providing individual patient data

Characteristics	Sources			
	Watterberg et al, 2004 ¹²	Peltoniemi et al, 2005 ¹³	Bonsante et al, 2007 ¹⁴	Baud et al, 2016 ¹⁵
Country	US	Finland	Italy	France
Funding source	National Institute of Child Health and Human Development	Foundation for Pediatric Research	University of Bari	Public Hospitals of Paris
Ethics Committee review	Yes	Yes	Yes	Yes
Parental informed consent	Yes	Yes	Yes	Yes
Loss to follow-up for primary outcome, n/N (%)	3/360 (<1)	None	None	2/523 (<1)
Design	Double-blind RCT	Double-blind RCT	Double-blind RCT	Double-blind RCT
Inclusion criteria				
Gestational age, wk		23 ^{0/7} -29 ^{6/7}	24 ^{0/7} -29 ^{6/7}	24 ^{0/7} -27 ^{6/7}
Birth weight, g	500-999 g	501-1250	500-1249	
Respiratory status	Need for mechanical ventilation at study entry	Need for mechanical ventilation before 24 h of life*	Need for mechanical ventilation after rescue surfactant	
Enrolled	Between 12 and 48 h postnatal age	Before 36 h	Before 48 h	Before 24 h
Duration of exposure	1 mg/kg/d for 12 d, then 0.5 mg/kg/d for 3 d	10 d tapered from 2.0 to 0.75 mg/kg/d	1 mg/kg/d divided into 2 doses/d for 9 d, then 0.5 mg/kg/d for 3 d	1 mg/kg/d divided into 2 doses/d for 7 d, then 0.5 mg/kg/d for 3 d

If an empty cell appears under inclusion criteria, the study did not have this criterion specified.

*A subgroup of infants with birth weight of 1000-1250 g had the additional requirement of supplemental oxygen and mechanical ventilation beyond 24 h despite surfactant therapy.

Table III. Patient characteristics and outcomes of 4 included studies providing individual patient data

Source	Watterberg et al, 2004 ¹²		Peltoniemi et al, 2005 ¹³		Bonsante et al, 2007 ¹⁴		Baud et al, 2016 ¹⁵	
	Hydrocortisone (n = 180)	Placebo (n = 180)	Hydrocortisone (n = 25)	Placebo (n = 26)	Hydrocortisone (n = 25)	Placebo (n = 25)	Hydrocortisone (n = 255)	Placebo (n = 266)
Birth weight, g, mean (SD)	730 (126)	734 (126)	888 (204)	903 (220)	840 (200)	869 (189)	867 (151)	862 (160)
Gestational age, wk, mean (SD)	25.2 (1.5)	25.3 (1.7)	26.7 (1.6)	26.9 (1.5)	26.2 (1.5)	26.3 (1.9)	26.4 (0.9)	26.4 (0.9)
Female sex, n (%)	84 (46.7)	90 (50.0)	9 (36.0)	12 (46.2)	12 (48.0)	9 (36.0)	124 (48.6)	117 (44.0)
Race, n (%)								
White	108 (60.0)	93 (51.7)	25 (100)	26 (100)	25 (100)	25 (100)	105/247 (42.5)	112/259 (43.2)
Black	65 (36.1)	70 (38.9)	0	0	0	0	101/247 (40.9)	96/259 (37.1)
Asian	3 (1.7)	12 (6.7)	0	0	0	0	8/247 (3.2)	12/259 (4.6)
Other	3 (1.7)	4 (2.2)	0	0	0	0	31/247 (12.6)	36/259 (13.9)
Unknown	1 (0.6)	1 (0.6)	0	0	0	0	2/247 (0.8)	3/259 (1.2)
Antenatal steroid use, n (%)	138 (76.7)	146 (81.1)	23 (92.0)	25 (96.2)	17 (68.0)	20 (80.0)	238 (93.3)	246 (92.8)
Rupture of membranes >24 h, n (%)	42/168 (25.0)	47/172 (27.3)	5 (20.0)	5 (19.2)			76 (29.8)	83 (31.2)
Vaginal delivery, n (%)	77 (42.8)	63 (35.0)	14 (56.0)	13 (50.0)	4 (16.0)	4 (16.0)	132/254 (52.0)	143/264 (54.2)
Histologic chorioamnionitis, n (%)	73/140 (52.1)	78/146 (53.4)	7/15 (46.7)	7/14 (50.0)	9 (36.0)	13 (52.0)	62/218 (28.4)	72/240 (30.0)
Preeclampsia, n (%)	24 (13.3)	30 (16.7)	4 (16.0)	6 (23.1)	8 (32.0)	4 (16.0)	34 (13.3)	23 (8.7)
Multiple birth, n (%)	42 (23.3)	38 (21.1)	5 (20.0)	7 (26.9)	4 (16.0)	5 (20.0)	82 (32.2)	90 (33.8)
Inborn, n (%)	152 (84.4)	165 (91.7)	25 (100)	26 (100)	25 (100)	25 (100)	255 (100)	266 (100)
Intubated at entry, n (%)	180 (100)	180 (100)	25 (100)	26 (100)	25 (100)	25 (100)	204 (80.0)	218 (82.0)
Age at entry, h, mean (SD)	31.4 (11.2)	33.1 (12.1); n = 178	27.2 (13.5); n = 24	21.5 (9.6)	13.5 (8.9)	13.3 (12.1)	15.2 (11.6); n = 253	14.4 (11.8); n = 265
Inotropic therapy at entry, n (%)	72 (40.0)	62 (34.4)	17 (68.0)	16 (61.5)	16 (64.0)	21 (84.0)	75 (29.4)	95 (35.7)
Outcomes at 36 wk PMA, n (%)								
Survival without BPD	73/179 (40.8)	67/178 (37.6)	16 (64.0)	14 (53.9)	16 (64.0)	8 (32.0)	153 (60.0)	136 (51.1)
Death	27/179 (15.1)	28/178 (15.7)	2 (8.0)	1 (3.9)	3 (12.0)	9 (36.0)	47 (18.4)	60 (22.6)
BPD	79/152 (52.0)	83/150 (55.3)	7/23 (30.4)	11/25 (44.0)	6/22 (27.3)	8/16 (50.0)	55/208 (26.4)	70/206 (34.0)
Weight, mean (SD)	2.01 (0.32); n = 150	2.03 (0.35); n = 147	2.00 (0.30); n = 22	1.95 (0.30); n = 24	1.74 (0.28); n = 21	1.81 (0.38); n = 14	2.09 (0.33); n = 197	2.11 (0.32); n = 194
Head circumference, cm, mean (SD)	31.2 (1.5); n = 147	30.9 (1.6); n = 145	31.8 (1.3); n = 22	31.2 (1.5); n = 23	30.7 (2.1); n = 17	30.7 (2.0); n = 14	30.8 (1.6); n = 160	30.8 (1.5); n = 155
Respiratory support								
Days of ventilation, median (IQR)	26 (9-50); n = 178	30 (13-46); n = 176	4 (2-17)	13 (3-40)	4 (2-21); n = 23	15 (2-27); n = 19		
Days of CPAP, median (IQR)			16 (2-28); n = 22	25 (17-32); n = 24	15 (5-27)	9 (0-20)		
Days of oxygen, median (IQR)	73 (40-102); n = 178	71 (32-95); n = 176	55 (35-91)	93 (41-162)	58 (26-72); n = 23	50 (28-76); n = 19		
Oxygen at discharge, n/N (%)	56/150 (37.3)	58/146 (39.7)	0/23	1/23 (4.4)	0/21	0/15	17/207 (8.2)	16/202 (7.9)
Open-label steroid use, n (%)	72 (40.0)	76 (42.2)	11 (44.0)	15 (57.7)	7 (28.0)	12 (48.0)	105 (41.2)	108 (40.6)
Pneumothorax, n (%)	23 (12.8)	18 (10.0)	1 (4.0)	3 (11.5)	2 (8.0)	4 (16.0)	5 (2.0)	7 (2.6)
Insulin treatment, n (%)	74 (41.1)	62 (34.4)	9 (36.0)	7 (26.9)	9 (36.0)	10 (40.0)	112 (43.9)	115 (43.2)
Treatment for PDA, n (%)								
Medical treatment (indomethacin or ibuprofen)	69 (38.3)	73 (40.6)	9 (36.0)	17 (65.4)	5 (20.0)	9 (36.0)	119 (46.7)	147 (55.3)
Any prophylactic indomethacin	127 (70.6)	123 (68.3)	4 (16.0)	8 (30.8)	0	0	0	0
Surgical ligation	26 (14.4)	21 (11.7)	5 (20.0)	7 (26.9)	0	0	37 (14.5)	55 (20.7)
Necrotizing enterocolitis, n (%)	7 (3.9)	14 (7.8)	2 (8.0)	1 (3.9)	1 (4.0)	2 (8.0)	17 (6.7)	12 (4.5)
Spontaneous gastrointestinal perforation, n/N (%)	17/178 (9.6)	4/180 (2.2)	4 (16.0)	0	1 (4.0)	0	13 (5.1)	11/(4.1)
Late-onset sepsis (bacterial/fungal), n (%)	80 (44.4)	73 (40.6)	8 (32.0)	4 (15.4)	8 (32.0)	5 (20.0)	80 (31.4)	66 (24.8)
Severe IVH (grade 3-4), n/N (%)	33/172 (19.2)	29/176 (16.5)	4 (16.0)	3 (11.5)	1 (4.0)	2 (8.0)	38 (14.9)	37 (13.9)
Cystic PVL, n/N (%)	12/142 (8.5)	10/142 (7.0)	5 (20.0)	3 (11.5)	1 (4.0)	2 (8.0)	4 (1.6)	10 (3.8)
Severe ROP, n/N (%)	41/153 (26.8)	47/150 (31.3)	1 (4.0)	1 (3.9)	4 (16.0)	4 (16.0)	4 (1.6)	2 (0.8)
Death before discharge, n (%)	31 (17.2)	32 (17.8)	2 (8.0)	3 (11.5)	4 (16.0)	10 (40.0)	48 (18.8)	67 (25.2)

CPAP, continuous positive airway pressure; IVH, intraventricular hemorrhage; PVL, periventricular leukomalacia; ROP, retinopathy of prematurity. For any cell with missing data, the denominator is provided within the cell. An empty cell indicates that not of the data were not available.

Table IV. Results of individual patient data meta-analysis of all outcomes adjusted for sex, gestational age, and any antenatal steroids

Outcomes	Hydrocortisone	Placebo	OR or Mean Difference	95% CI of OR or Mean Difference	P Value
Survival without BPD at 36 wk PMA, n/N (%)	258/484 (53.3)	225/495 (45.5)	1.45	1.11-1.90	.007
Death before 36 wk PMA, n/N (%)	79/484 (16.3)	98/495 (19.8)	0.76	0.54-1.07	.12
BPD at 36 wk PMA, n/N (%)	147/405 (36.3)	172/397 (43.3)	0.73	0.54-0.98	.038
Death before discharge, n/N (%)	85/485 (17.5)	112/497 (22.5)	0.70	0.51-0.97	.0327
Weight at 36 wk PMA, g, mean	2036 (n = 390)	2061 (n = 379)	-24.11	-71.36 to 23.14	.32
Head circumference at 36 wk, cm, mean	31.0 (n = 346)	30.9 (n = 337)	0.19	-0.05 to 0.42	.12
Respiratory support					
Days of ventilation, mean	32.3 (n = 226)	31.7 (n = 221)	-0.63	-7.28 to 6.01	.85
Days of CPAP, mean	17.2 (n = 47)	17.7 (n = 49)	-0.12	-5.78 to 5.55	.97
Days of oxygen, mean	74.1 (n = 226)	75.2 (n = 221)	-2.17	-12.07 to 7.73	.67
Oxygen at discharge, n/N (%)	73/401 (18.2)	75/386 (19.4)	0.92	0.64-1.33	.65
Open-label steroid use, n/N (%)	195/485 (40.2)	211/497 (42.5)	0.90	0.70-1.17	.44
Pneumothorax, n/N (%)	31/485 (6.39)	32/497 (6.44)	0.98	0.58-1.64	.93
Insulin treatment, n/N (%)	204/485 (42.1)	194/497 (39.0)	1.12	0.86-1.45	.42
Medical treatment for PDA (indomethacin or ibuprofen), n/N (%)	202/485 (41.7)	246/497 (49.5)	0.72	0.56-0.93	.012
Any prophylactic indomethacin, n/N (%)	61/485 (12.6)	63/497 (12.7)	0.96	0.65-1.41	.83
Surgical ligation, n/N (%)	68/485 (14.0)	83/497 (16.7)	0.80	0.56-1.14	.21
Necrotizing enterocolitis, n/N (%)	27/485 (5.57)	29/497 (5.84)	0.95	0.55-1.63	.85
Spontaneous gastrointestinal perforation	35/483 (7.25)	15/497 (3.02)	2.50	1.33-4.69	.004
Late-onset sepsis (bacterial/fungal), n/N (%)	176/485 (36.3)	148/497 (29.8)	1.34	1.02-1.75	.0357
Severe IVH (grade 3-4), n/N (%)	76/477 (15.9)	71/493 (14.4)	1.10	0.76-1.59	.60
Cystic PVL, n/N (%)	22/447 (4.92)	25/459 (5.45)	0.89	0.49-1.60	.69
Severe ROP, n/N (%)	50/458 (10.9)	54/467 (11.6)	0.92	0.59-1.45	.72

pneumothorax, necrotizing enterocolitis, severe intraventricular hemorrhage, cystic periventricular leukomalacia, and severe retinopathy of prematurity. There also were no significant differences in weight or head circumference at 36 weeks PMA between the 2 groups.

Table VI. Subgroup analyses of primary outcome and other selected outcomes adjusted for sex, gestational age, and any antenatal steroids unless the adjustment factor is used to define the subgroup

Outcomes	OR	95% CI	P value
Survival to 36 wk without BPD			
Male	1.40	0.97-2.02	.074
Female	1.52	1.02-2.26	.038
Gestational age <26 wk	1.38	0.91-2.09	.13
Gestational age ≥26 wk	1.52	1.07-2.17	.020
No chorioamnionitis	1.40	0.97-2.02	.074
Chorioamnionitis	2.01	1.19-3.39	.009
Death before discharge			
Male	0.73	0.47-1.14	.17
Female	0.66	0.41-1.07	.094
Gestational age <26 wk	0.87	0.58-1.32	.53
Gestational age ≥26 wk	0.46	0.26-0.82	.008
No chorioamnionitis	0.71	0.44-1.15	.16
Chorioamnionitis	0.43	0.23-0.82	.010
Late-onset sepsis			
Male	1.41	0.96-2.05	.076
Female	1.23	0.83-1.83	.29
Gestational age <26 wk	1.60	1.08-2.37	.019
Gestational age ≥26 wk	1.14	0.78-1.65	.50
No chorioamnionitis	1.06	0.72-1.55	.77
Chorioamnionitis	1.91	1.18-3.08	.009
Spontaneous gastrointestinal perforation			
No indomethacin	1.52	0.73-3.15	.26
Indomethacin	9.37	2.02-43.49	.004

Planned Subgroup Analyses

Table VI summarizes the effect of treatment group on the primary study outcome as well as on late-onset sepsis and mortality before discharge, by subgroup of interest (sex, gestational age, histologic chorioamnionitis, and indomethacin exposure) adjusted for sex, gestational age, and any antenatal steroids unless the adjustment factor is used to define the subgroup of interest. Although individual odds ratios vary somewhat among subgroups, the effect is generally consistent for improvement in survival without BPD at 36 weeks PMA. Of particular interest is that the effect was similar for boys and girls. The outcomes for the subgroup chorioamnionitis showed that the incidence of late-onset sepsis was significantly increased (OR, 1.91; 95% CI, 1.18-3.08), but at the same time the incidence of survival without BPD was increased (OR, 2.01; 95% CI, 1.19-3.39) and mortality before discharge was decreased (OR, 0.43; 95% CI, 0.23-0.82).

The results of the individual patient data meta-analysis were compared with aggregate meta-analysis based on the published data of the four studies included. For the aggregate meta-analysis of the four studies, there was no significant difference in the odds of survival without BPD at 36 weeks PMA (OR, 1.40; 95% CI, 0.98-2.00).

Long-Term Outcomes

Because of differences in assessment tools used (the Griffiths Developmental Scale, Bayley Scale of Infant Development, and revised Brunet-Lezine Scale), only cerebral palsy (CP) and NDI were compared in 709 of 785 (90%) and 706 of 785 (90%) children at age 2 years, respectively, using aggregate meta-analysis. These analyses were performed based on the available data collected from the 4 RCTs included in the individual patient data

meta-analysis (Table VII; available at www.jpeds.com).¹⁶⁻¹⁸ Hydrocortisone therapy did not show a significant benefit; however, the direction of effect consistently favored the hydrocortisone-treated group for NDI (OR, 0.76; 95% CI, 0.52-1.12). For CP, individual study results were mixed in direction, but overall there was no significant relationship between hydrocortisone exposure and CP (OR, 0.95; 95% CI, 0.56-1.60).

Discussion

In this study, an individual patient data meta-analysis of 4 published RCTs showed that early low-dose hydrocortisone treatment in very preterm infants was associated with significantly increased survival without BPD, as well as a decreased need for PDA treatment and reduced mortality before discharge. The fifth published study of this therapy, a 40-patient pilot RCT for which data were no longer available, also showed a benefit; therefore, its omission does not affect the conclusions of our analysis.¹¹

Other findings of note include a significant decrease in the incidence of treatment for PDA in infants treated with hydrocortisone. We have previously reported significantly lower cortisol concentrations in infants diagnosed with PDA, as well as in infants who subsequently develop BPD,^{4,9,32} suggesting that adrenal insufficiency may be a contributing factor to the well-known association of PDA with BPD.³³ In addition, in the absence of indomethacin exposure, hydrocortisone therapy did not have an effect on the incidence of spontaneous gastrointestinal perforation. Studies in which ibuprofen was used as treatment for PDA also reported no effect of hydrocortisone therapy on perforation.^{14,15,17}

Our analysis confirms an association between early low-dose hydrocortisone exposure and late-onset sepsis; nonetheless, treatment was associated with a significantly improved survival without BPD at 36 weeks PMA and survival to discharge, with no adverse effects on neurodevelopmental outcomes at 2 years.¹⁶⁻¹⁹ Follow-up of a small number of children (n = 27) at age 5-7 years suggested a correlation between early hydrocortisone treatment and later neurocognitive impairment³⁴; however, the 2-year outcomes of 694 children enrolled in all these studies showed no adverse neurodevelopmental effects and identified possible benefits. Longer-term follow-up of previous cohort studies also have been reassuring.³⁵ Children in the PREMILOC study will be assessed at age 5-7 years.¹⁸

Planned subgroup analyses showed that hydrocortisone appears to be similarly efficacious for both boys and girls. The direction of effect was beneficial in both gestational age strata; however, effects were more pronounced in the infants born at ≥ 26 weeks of gestation, consistent with the increased fragility and resistance to therapies of the most immature infants.² In the presence of chorioamnionitis, the incidence of late-onset sepsis was increased with hydrocortisone therapy, but a benefit was still seen in the primary outcome and in survival to discharge. Chorioamnionitis is a risk factor for late-onset sepsis³⁶; treatment with hydrocortisone may affect the immune response, yet reduce inflammatory injury and

thereby improve outcomes in exposed infants, because systemic inflammation has been shown to precede clinical symptoms of the early phase of BPD.⁵ As always, subgroup analyses, even when preplanned, should be interpreted with caution.

Only 5 trials, including the 4 included in this analysis and that reported by Watterberg et al in 1999,¹¹ were specifically designed to assess the effect of early low-dose hydrocortisone as prophylaxis of early adrenal insufficiency in very preterm infants. Four other RCTs tested the effect of early hydrocortisone in hypotensive preterm infants,²⁷⁻³⁰ including 1 trial testing hydrocortisone in association with dopamine³⁰ and 1 trial investigating the effect of early triiodothyronine therapy on mortality and respiratory morbidity that included low-dose hydrocortisone as an adjunct therapy.³¹ Those studies found no significant benefit in survival without BPD at 36 weeks; however, the shorter treatment periods in those studies might have affected their results. We have reported lower cortisol concentrations and a decreased response to ACTH stimulation continuing beyond the first postnatal week in infants who subsequently developed BPD.^{9,32,37}

Strengths of this study include access to individual patient data for 982 patients, harmonization of data and outcome definitions across studies, and very close comparability of the study populations and the therapeutic intervention. Our results differ from those of an aggregate meta-analysis of the 4 studies showing no difference in the odds of survival without BPD at 36 weeks PMA, demonstrating that an individual patient data meta-analysis can improve the ability to address important confounders at the individual patient level.

Limitations of the study include the loss of 40 patients in the original pilot study¹¹ and loss of accuracy regarding the time of first dose. In addition, exposure to indomethacin as a confounding variable was not balanced across all studies.

In conclusion, this individual patient data meta-analysis shows that early, low-dose hydrocortisone therapy provides significant benefits in survival without BPD, PDA closure, and survival to discharge in very preterm infants. Increases in intestinal perforation and late-onset sepsis, 2 reported adverse effects of this hydrocortisone treatment, did not appear to negate the overall benefits of hydrocortisone in this population. ■

Submitted for publication May 17, 2018; last revision received Oct 1, 2018; accepted Oct 3, 2018

Reprint requests: Olivier Baud, MD, PhD, Division of Neonatology, Department of Pediatrics, University Hospitals, Rue Willy-Donzé 6, 1205 Genève, Geneva, Switzerland. E-mail: olivier.baud@hcuge.ch

References

1. Jensen EA, Schmidt B. Epidemiology of bronchopulmonary dysplasia. *Birth Defects Res A Clin Mol Teratol* 2014;100:145-57.
2. Stoll BJ, Hansen NI, Bell EF, Walsh MC, Carlo WA, Shankaran S, et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. *JAMA* 2015;314:1039-51.
3. Balany J, Bhandari V. Understanding the impact of infection, inflammation, and their persistence in the pathogenesis of bronchopulmonary dysplasia. *Front Med (Lausanne)* 2015;2:90.

4. Watterberg KL, Scott SM, Backstrom C, Gifford KL, Cook KL. Links between early adrenal function and respiratory outcome in preterm infants: airway inflammation and patent ductus arteriosus. *Pediatrics* 2000;105:320-4.
5. Leroy S, Caumette E, Waddington C, Hébert A, Brant R, Lavoie PM. A time-based analysis of inflammation in infants at risk of bronchopulmonary dysplasia. *J Pediatr* 2018;192:60-5.e1.
6. Doyle LW, Ehrenkranz RA, Halliday HL. Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. *Cochrane Database Syst Rev* 2014;5:CD001146.
7. Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Early (<8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. *Cochrane Database Syst Rev* 2017;10:CD001146.
8. Jobe AH. Mechanisms of lung injury and bronchopulmonary dysplasia. *Am J Perinatol* 2016;33:1076-8.
9. Watterberg KL, Scott SM. Evidence of early adrenal insufficiency in babies who develop bronchopulmonary dysplasia. *Pediatrics* 1995;95:120-5.
10. Huysman MW, Hokken-Koelega AC, De Ridder MA, Sauer PJ. Adrenal function in sick very preterm infants. *Pediatr Res* 2000;48:629-33.
11. Watterberg KL, Gerdes JS, Gifford KL, Lin HM. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. *Pediatrics* 1999;104:1258-63.
12. Watterberg KL, Gerdes JS, Cole CH, Aucott SW, Thilo EH, Mammel MC, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. *Pediatrics* 2004;114:1649-57.
13. Peltoniemi O, Kari MA, Heinonen K, Saarela T, Nikolajev K, Andersson S, et al. Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. *J Pediatr* 2005;146:632-7.
14. Bonsante F, Latorre G, Iacobelli S, Forziati V, Laforgia N, Esposito L, et al. Early low-dose hydrocortisone in very preterm infants: a randomized, placebo-controlled trial. *Neonatology* 2007;91:217-21.
15. Baud O, Maury L, Lebail F, Ramful D, El Moussawi F, Nicaise C, et al. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMLOC): a double-blind, placebo-controlled, multicentre, randomised trial. *Lancet* 2016;387:1827-36.
16. Watterberg KL, Shaffer ML, Mishefske MJ, Leach CL, Mammel MC, Couser RJ, et al. Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. *Pediatrics* 2007;120:40-8.
17. Peltoniemi OM, Lano A, Puosi R, Yliherva A, Bonsante F, Kari MA, et al. Trial of early neonatal hydrocortisone: two-year follow-up. *Neonatology* 2009;95:240-7.
18. Baud O, Trousson C, Biran V, Leroy E, Mohamed D, Alberti C. Association between early low-dose hydrocortisone therapy in extremely preterm neonates and neurodevelopmental outcomes at 2 years of age. *JAMA* 2017;317:1329-37.
19. Baud O, Trousson C, Biran V, Leroy E, Mohamed D, Alberti C. Two-year neurodevelopmental outcomes of extremely preterm infants treated with early hydrocortisone: treatment effect according to gestational age at birth. *Arch Dis Child Fetal Neonatal Ed* 2018. doi: 10.1136/archdischild-2017-313756. [Epub ahead of print].
20. Doyle LW, Ehrenkranz RA, Halliday HL. Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. *Neonatology* 2010;98:111-7.
21. Lambert PC, Sutton AJ, Abrams KR, Jones DR. A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. *J Clin Epidemiol* 2002;55:86-94.
22. Berlin JA, Santanna J, Schmid CH, Szczech LA, Feldman HI. Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head. *Stat Med* 2002;21:371-87.
23. Higgins JP, Thompson SG. Controlling the risk of spurious findings from meta-regression. *Stat Med* 2004;23:1663-82.
24. Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. *Biometrics* 1997;53:983-97.
25. Fitzmaurice GM, Laird NM, Ware JH. *Applied longitudinal analysis*. 2nd ed. Hoboken (NJ): John Wiley & Sons; 2011.
26. Baden M, Bauer CR, Colle E, Klein G, Taeusch HW Jr, Stern L. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. *Pediatrics* 1972;50:526-34.
27. Efield MM, Heerens AT, Gordon PV, Bose CL, Young DA. A randomized-controlled trial of prophylactic hydrocortisone supplementation for the prevention of hypotension in extremely low birth weight infants. *J Perinatol* 2005;25:119-24.
28. Ng PC, Lee CH, Bnur FL, Chan IH, Lee AW, Wong E, et al. A double-blind, randomized, controlled study of a "stress dose" of hydrocortisone for rescue treatment of refractory hypotension in preterm infants. *Pediatrics* 2006;117:367-75.
29. Batton BJ, Li L, Newman NS, Das A, Watterberg KL, Yoder BA, et al. Feasibility study of early blood pressure management in extremely preterm infants. *J Pediatr* 2012;161:65-9.e1.
30. Hochwald O, Palegra G, Osiovič H. Adding hydrocortisone as first line of inotropic treatment for hypotension in very low birth weight infants. *Indian J Pediatr* 2014;81:808-10.
31. Biswas S, Buffery J, Enoch H, Bland M, Markiewicz M, Walters D. Pulmonary effects of triiodothyronine (T3) and hydrocortisone (HC) supplementation in preterm infants less than 30 weeks gestation: results of the THORN trial: Thyroid Hormone Replacement in Neonates. *Pediatr Res* 2003;53:48-56.
32. Watterberg KL, Gerdes JS, Cook KL. Impaired glucocorticoid synthesis in premature infants developing chronic lung disease. *Pediatr Res* 2001;50:190-5.
33. Schena F, Francescato G, Cappelleri A, Piccioli I, Mayer A, Mosca F, et al. Association between hemodynamically significant patent ductus arteriosus and bronchopulmonary dysplasia. *J Pediatr* 2015;166:1488-92.
34. Peltoniemi OM, Lano A, Yliherva A, Kari MA, Hallman M; Neonatal Hydrocortisone Working Group. Randomised trial of early neonatal hydrocortisone demonstrates potential undesired effects on neurodevelopment at preschool age. *Acta Paediatr* 2016;105:159-64.
35. Rademaker KJ, de Vries WB. Long-term effects of neonatal hydrocortisone treatment for chronic lung disease on the developing brain and heart. *Semin Fetal Neonatal Med* 2009;14:171-7.
36. Gowda H, Norton R, White A, Kandasamy Y. Late-onset neonatal sepsis: a 10-year review from North Queensland, Australia. *Pediatr Infect Dis J* 2017;36:883-8.
37. Watterberg KL, Shaffer ML, Garland JS, Thilo EH, Mammel MC, Couser RJ, et al. Effect of dose on response to adrenocorticotropin in extremely low birth weight infants. *J Clin Endocrinol Metab* 2005;90:6380-5.

Appendix

Brief Statistical Analysis Plan for Hydrocortisone Meta-Analysis

Overview. Five RCTs that tested low-dose hydrocortisone during the first postnatal days with the primary outcome of improving survival without BPD have been completed and published. Individual patient data are no longer available for the first trial of 40 patients. We will conduct an individual patient data meta-analysis of the remaining 4 trials. Although this individual patient data meta-analysis was not prospectively planned, the studies are quite similar in hypothesis, design, and primary outcome. Patient eligibility varies slightly across the studies, as do the dose and duration of hydrocortisone therapy; however, these differences are minor, and the populations generally overlap.

Data Analysis. Descriptive data will be presented for each study when available, and overall, including the variables shown in **Appendix Table I**. We will take a 1-step approach to individual patient data meta-analysis using generalizations of logistic regression models for binary outcomes and linear regression models for quantitative outcomes based on generalized linear mixed models with Kenward-Rogers approximation of degrees of freedom. We will account for clustering of patients within different studies by specifying a random intercept term, assuming that the baseline is drawn at random from a normal distribution. We will consider treatment a random effect and adjustment factors random effects. We will assume different residual variances for each study because

patient eligibility varies slightly from study to study, as well as dose and duration of hydrocortisone therapy. Simplifications of modeling assumptions, such as fixed effects in place of random effects and a common residual variance, will be considered if models fail to converge.

The primary outcome of interest is the binary variable survival without BPD at 36 weeks, and the primary predictor is receipt of hydrocortisone treatment. Primary and secondary outcomes of interest are summarized in **Appendix Table II**. Adjustment variables included in all models are birth weight, sex, gestational age, antenatal steroids, and age at first dose.

Similar subgroup analyses will be conducted for the following groups: boys/girls, histologic chorioamnionitis, gestational age strata, and receipt of indomethacin.

References

1. Bonsante F, Latorre G, Iacobelli S, Forziati V, Laforgia N, Esposito L, et al. Early low-dose hydrocortisone in very preterm infants: a randomized, placebo-controlled trial. *Neonatology* 2007;91:217-21.
2. Peltoniemi O, Kari MA, Heinonen K, Saarela T, Nikolajev K, Andersson S, et al. Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. *J Pediatr* 2005;146:632-7.
3. Watterberg KL, Gerdes JS, Cole CH, Aucott SW, Thilo EH, Mammel MC, et al. Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. *Pediatrics* 2004;114:1649-57.
4. Baud O, Maury L, Lebail F, Ramful D, El Moussawi F, Nicaise C, et al. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. *Lancet* 2016;387:1827-36.

Appendix Table I. Descriptive variables to be summarized overall and by study

Variable	Availability				Scale
	Bonsante et al, 2007 ¹	Peltoniemi et al, 2005 ²	Watterberg et al, 2004 ³	Baud et al, 2016 ⁴	
Birth weight	Y	Y	Y	Y	Quantitative (g)
Gestational age	Y	Y	Y	Y	Quantitative (wk)
Sex	Y	Y	Y	Y	Binary
Apgar 1-min score	Y	Y	Y	N	Quantitative
Apgar 5-min score	Y	Y	Y	Y	Quantitative
Race/ethnicity	Y	All white	Y	Y	Categorical: 1, white; 2, black; 3, Asian; 4, other; 9, unknown
Antenatal steroids	Y (any/full)	Y (any/full/partial)	Y (detailed)	Y	Binary (any vs none)
Rupture of membranes	N	>24 h Y/N	Y (h)	Y (>24 h)	Binary (>24 h Y/N)
Vaginal/Cesarean delivery	Y	Y	Y	Y	Binary
Chorioamnionitis	Y (histologic)	Y (histologic)/Y (clinical)	Y (histologic detailed, clinical)	Y (histologic/ clinical)	Binary (histologic Y/N); binary (clinical Y/N)
Preeclampsia	Y	Y	Y	Y	Binary
Multiple birth	Y (individual random)	Y (individual random)	Y (twin, random together)	Y (how random?)	Binary (Y/N)
Inborn/outborn	Y (all inborn)	Y (all inborn)	Y	Y (inborn)	Binary
Intubated at entry	Y (all)	Y (all)	Y (all)	Y (both)	Binary
Age at entry	Y (at first dose)	Y (at first dose)	Y (at first dose)	Y (at first dose)	Quantitative, h
CRIB score	Y	N	Y	N	Quantitative
Blood pressure					
Daily	N	Y	Y	Y	Daily systolic
Inotropic therapy at study entry	Y	Y	Y	Y	Binary (any Y/N)

CRIB, Clinical Risk Index for Babies.

Appendix Table II. Primary and secondary outcomes

Outcomes	Availability				Scale
	Bonsante et al, 2007 ¹	Peltoneimi et al, 2005 ²	Watterberg et al, 2004 ³	Baud et al, 2016 ⁴	
Survival without BPD	Y (clinical)	Y (clinical)	Y (clinical, physiological)	Y (physiological)	Binary (Y/N clinical and Y/N physiological)
Severity at 36 wk	FiO ₂ >30%/vent; Home on O ₂	FiO ₂ /CPAP/vent	FiO ₂ /MAP/vent/CPAP	FiO ₂ /MAP/vent/CPAP	Categorical (moderate, O ₂ <30% at 36 wk; severe, >30% or any positive pressure)
Days of ventilation/CPAP/oxygen	Y/Y/Y	Y/Y/Y	Y/N/Y	N/N/N	Quantitative
Oxygen at discharge	Y	Y	Y	N	Binary
Pneumothorax/pulmonary interstitial emphysema	Y/N	Y/N	Y/Y	Y/N	Binary/binary
PDA treatment	Y	Y (indomethacin/ibuprofen/ligation/other)	Y (indomethacin/ligation/other)	Y (ibuprofen/ligation)	Binary (any treatment Y/N)
Insulin treatment	Y	Y	Y	Y	Binary
Necrotizing enterocolitis	Y	Y	Y (stage)	Y	Binary
Gastrointestinal perforation/indomethacin	Y/Y	Y/Y	Y/Y	Y (ibuprofen)	Binary/binary
Late-onset sepsis (bacterial or fungal)	Y	Y	Y	Y	Binary/binary
IVH grade 3-4/PVL	Y/Y	Y/Y	Y/Y	Y severe/Y	Binary (severe Y/N)/binary
ROP grade	Y	Y	Y	Y (severe)	Binary (severe Y/N)
Death before discharge	Y	Y	Y	Y	Binary
36 wk weight and head circumference	Y z-scores	Y actual values	Y actual values; length not available	Y actual values	z-scores
Open-label steroid use/type of steroid use	Y (dex BPD hydrocortisone-BP)	Y (+ inhaled)	Y (dex all)	Y (Y, inhaled)	Binary (use Y/N); binary (inhaled Y/N); binary (systemic Y/N)
Any indomethacin exposure	Ibuprofen prophylaxis for PDA	Indomethacin Rx	Prenatal or subsequent indomethacin Rx	Ibuprofen	Any exposure (Y/N)

CPAP, continuous positive airway pressure; IVH, intraventricular hemorrhage; MAP, mean airway pressure; PVL, periventricular leukomalacia; ROP, retinopathy of prematurity.




Figure. PRISMA-IPD flow diagram.

Table I. RCTs using early hydrocortisone in preterm neonates and selection of studies in individual patient meta-analysis

Study		Dosage	Cotreatment	Exposure	Population	Number of Patients	Included in Individual Patient Data	Excluded in Individual Patient Data	Reason for Exclusion
Authors	Year								
Baden et al ²⁶	1972	15 mg/kg	No	12 h	26-36 wk with respiratory distress syndrome	44		X	Dosage; duration <7 d
Watterberg et al ¹¹	1999	0.5-1 mg/kg/d	No	12 d	500-999 g, ventilated	40		X	Data not available
Watterberg et al ¹²	2004	0.5-1 mg/kg/d	No	12 d	500-999 g, ventilated	360	X		Data not available
Biswas et al ³¹	2003	0.5-1 mg/kg/d	Yes (triiodothyronine)	5 d	<30 wk, ventilated	253		X	Cotreatment, duration <7 d
Efird et al ²⁷	2005	0.3-1 mg/kg/d	No	5 d	24-28 wk and <1000 g, with hypotension	34		X	Duration <7 d
Peltoniemi et al ¹³	2005	0.75-2 mg/kg/d	No	10 d	<31 wk or <1251 g, ventilated	51	X		
Ng et al ²⁸	2006	1 mg/kg/8 h	No	5 d	<1500 g, refractory hypotension	48		X	Dosage; duration <7 d
Bonsante et al ¹⁴	2007	0.5-1 mg/kg/d	No	12 d	24-30 wk or <1250 g, ventilated	50	X		
Batton et al ²⁹	2012	0.5-1 mg/kg/12 h	Yes (dopamine)	3.5 d	23-26 wk with hypotension	10		X	Cotreatment; duration <7 d
Hochwald et al ³⁰	2014	0.5-2 mg/kg/6 h	No	48 h	<31 wk or <1251 g, hypotension	22		X	Duration <7 d
Baud et al ¹⁵	2016	0.5-1 mg/kg/d	No	10 d	24-28 wk, all but severe intrauterine growth retardation	523	X		

Table V. Heterogeneity estimates of individual patient data meta-analysis of all outcomes unadjusted

Outcomes	Heterogeneity	
	I ² %	P Value
Survival without BPD at 36 wk PMA	0	.298
Death before 36 wk PMA	0	.310
BPD at 36 wk PMA	0	.621
Death before discharge	0	.397
Weight at 36 wk PMA, g	0	.853
Head circumference at 36 wk, cm	0	.463
Respiratory support		
Days of ventilation	0	.464
Days of CPAP	67.9	.078
Days of oxygen	54.0	1.14
Oxygen at discharge	0	.949
Open-label steroid use	0	.433
Pneumothorax	0	.459
Insulin treatment	0	.722
Medical treatment for PDA (either indomethacin or ibuprofen)	0	.261
Any prophylactic indomethacin	0	.191
Surgical ligation	13.7	.218
Necrotizing enterocolitis	19.6	.238
Spontaneous gastrointestinal perforation	31.9	.322
Late sepsis (bacterial/fungal)	0	.662
Severe VH (grade 3-4)	0	.887
Cystic PVL	0	.338
Severe ROP	0	.759

Aggregate meta-analysis: Cr: I² = 0%, P = .726 NDI: I² = 0%, P = .897; BPD: I² = 30.9%, P = .227.

Table VII. Characteristics of the studies in the long-term outcomes meta-analysis

Characteristics	Watterberg et al, 2007 ¹⁶		Peltoniemi et al, 2009 ¹⁷		Bonsante et al, 2007 follow-up study as reported in Peltoniemi et al, 2009 ¹⁷		Baud et al, 2017 ¹⁸	
	Hydrocortisone	Placebo	Hydrocortisone	Placebo	Hydrocortisone	Placebo	Hydrocortisone	Placebo
Treatment group								
Survivors at follow-up, n	146	145	23	23	20	14	207	199
Lost to follow-up, n (%)	20 (13.7)	19 (13.1)	0	1 (4.35)	0	0	13 (6.28)	14 (7.04)
Age at follow-up, yr		2		2		2		2
Type of assessment used	BSID-II		BSID-II and Griffiths Developmental Scale		BSID-II		Revised Brunet- Lezine Scale and standardized neurologic exam	
Cutoff score defining severe NDI	DQ <70		MDI or DQ <70		DQ <70		DQ <70	
CP,* n/N (%)	16/126 (12.7)	18/126 (14.3)	2/23 (8.70)	0/22 (0)	2/19 (10.5)	2/14 (14.3)	12/194 (6.19)	10/185 (5.41)
NDI, n/N (%)	48/123 (39.0)	55/125 (44.0)	5/23 (21.7)	5/22 (22.7)	4/20 (20.0)	3/14 (21.4)	14/194 (7.22)	21/185 (11.4)

BSID, Bayley Scale of Infant Development; DQ, developmental quotient; MDI, mental developmental index.

*All levels of CP.